In August 2025, AbbVie organized a study is to assess adverse events and change in disease activity when Telisotuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback